CN100497384C - Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same - Google Patents
Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same Download PDFInfo
- Publication number
- CN100497384C CN100497384C CNB018122795A CN01812279A CN100497384C CN 100497384 C CN100497384 C CN 100497384C CN B018122795 A CNB018122795 A CN B018122795A CN 01812279 A CN01812279 A CN 01812279A CN 100497384 C CN100497384 C CN 100497384C
- Authority
- CN
- China
- Prior art keywords
- zaa
- peptide
- glu
- gnrh
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 144
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 title claims abstract description 63
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 title claims abstract description 62
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 title claims abstract description 61
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 title claims abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 39
- 239000002243 precursor Substances 0.000 title claims description 25
- 108090000623 proteins and genes Proteins 0.000 title description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 42
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 22
- 150000001413 amino acids Chemical class 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims description 17
- 210000004556 brain Anatomy 0.000 claims description 15
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000013467 fragmentation Methods 0.000 claims description 6
- 238000006062 fragmentation reaction Methods 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 claims description 3
- 241000238414 Octopus vulgaris Species 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 241000238413 Octopus Species 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 22
- 241001465754 Metazoa Species 0.000 abstract description 11
- 230000007246 mechanism Effects 0.000 abstract description 7
- 241000237852 Mollusca Species 0.000 abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000575 pesticide Substances 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 150000007514 bases Chemical class 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 abstract 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 abstract 2
- 210000005036 nerve Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 42
- 239000000203 mixture Substances 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000004087 circulation Effects 0.000 description 12
- 241000286209 Phasianidae Species 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 102000009151 Luteinizing Hormone Human genes 0.000 description 7
- 108010073521 Luteinizing Hormone Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 206010062767 Hypophysitis Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 101710102229 Progonadoliberin-2 Proteins 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 230000012447 hatching Effects 0.000 description 6
- 210000003635 pituitary gland Anatomy 0.000 description 6
- 108090000189 Neuropeptides Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000003797 Neuropeptides Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 210000000692 cap cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000010365 information processing Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000238366 Cephalopoda Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000005112 optic tract Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- UAYHBJIRVVTXIJ-XSTSSERXSA-N (3s)-3-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[2-[[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phe Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(N)=O)CC1=CC=CC=C1 UAYHBJIRVVTXIJ-XSTSSERXSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
- PDSPNGGVEIUMHV-UHFFFAOYSA-N 2-methylindole Chemical compound C1=C[CH]C2=NC(C)=CC2=C1 PDSPNGGVEIUMHV-UHFFFAOYSA-N 0.000 description 1
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-metylindole Natural products C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 1
- NKMJZJDVLMDPGO-UHFFFAOYSA-N 5,8-dihydroxy-2-(2-phenylethyl)chromen-4-one Chemical compound OC1=CC=C(O)C(C(C=2)=O)=C1OC=2CCC1=CC=CC=C1 NKMJZJDVLMDPGO-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- -1 9-fluorenyl methoxy carbonyl Chemical group 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101800000164 FMRF-amide Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010003828 buccalin Proteins 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000026109 gonad development Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UIBASYXNWHWBOR-UBZWXBNLSA-N n-[2-[[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-1-[(2s)-2-aminopropanoyl]pyrrolidine-2-carboxamide Chemical compound C[C@H](N)C(=O)N1CCCC1C(=O)NCC(=O)N[C@H](C(N)=O)CC1=CNC2=CC=CC=C12 UIBASYXNWHWBOR-UBZWXBNLSA-N 0.000 description 1
- 230000002644 neurohormonal effect Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/857—Fish; fish eggs; shell fish; crustacea
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A novel gonadotropin-releasing hormone (GnRH) occurring in octopus which is a mollusk is found out and the structure and action thereof are clarified, thereby providing novel peptides which are usable as reagents for clarifying the correlation between the structure and activity of GnRH and signal processing mechanism in the nerve system of higher animals and as basic compounds for developing pesticides or drugs. Namely, peptides represented by the following amino acid sequence formula (I) and having a GnRH activity: <Glu-Zaa-Zaa-His-Zaa-Ser-Zaa-Zaa-Zaa Zaa-Pro-Gly-NH2 (I) wherein <Glu represents pyroglutamic acid; and Zaa represent an arbitrary amino acid; in particular, a peptide represented by the following amino acid sequence formula (1): <Glu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH2 (I) wherein <Glu represents pyroglutamic acid.
Description
Technical field
The present invention relates to novel neuropeptide, more specifically relate to the brain (comprising optic gland, tractus opticus, optic lobe) from octopus (Octopusvulgaris) acquisition and have the active novel peptide of gonadotropin-releasing hormone (GnRH).The present invention also relates to this propeptide polypeptide and encoding gene thereof.
Background technology
Invertebrates has the endocrine system with the parallel complexity of growing of their neural system.We know that in invertebrates, multiple endogenous peptide is as neurotransmitter, neuromodulator or neurohormonal.
With respect to higher animal, mollusk generally has better simply neural system. therefore, their neural system can be used as the useful tool of research information processing mechanism. generally believe, on cell levels, obtain about the knowledge of molluscan information processing mechanism applicable to the neural information processing mechanism of higher animal.Therefore, people have done sizable effort and have sought molluscan neurotransmitter.
For example, the open NO.Hei1-221392 of Japanese Patent discloses the endogenous neuropeptide that obtains from shellfish.The open NO.Hei2-286696 of Japanese Patent discloses a kind of novel peptide that is separated to from the neuroganglion of African Snail.This peptide contains D-amino acid, and finds that they can be used as endogenous neurotransmitter.The open NO.Hei6-56890 of Japanese Patent discloses a kind of neuropeptide that is separated to from the neuroganglion of Hungary snail.
Outside foregoing description, from mollusk, be separated to other multiple neuropeptides, and they have been identified.Example comprises Ala-Pro-Gly-Trp-NH
2, myomodulin-CARP, can cardioactive little peptide (SCP), buccalin and Phe-Met-Arg-Phe-NH2 (FMRF-acid amides) (M.Kobayashi and Y.Muneoka, Zool.Sci., 7,801 (1990); Y.Muneoka and M.Mobayashi, Experimentia 48,448 (1992); Youjiro.Muneoka, Journal of Pesticide Science, 18, S191 (1993); Y.Muneoka, T.Takahashi, M.Kobayashi, " Perspective inComparative Endocrinology ", National Research Council ofCanada, 1994, p109; A.Di Cosmo and C.Di Cristo, J.Comp.Neurol., 398,1-12 (1998)).
Mollusk is one of maximum invertebrates family. mollusk has multiple different kind, and octopus belongs to Cephalopoda.With respect to other mollusk member, these animals have highly developed brain and more flourishing motion and sensory function.Neurosecretory system to octopus has been carried out extensive studies.1956, Boycott and Young found that the tractus opticus of cutting off this animal can cause optic gland to increase and gonad development.After this, Wells has proved glandular secretion gonad-stimulating hormone (M.J.Wells and J.Wells, J.Exp.Biol., 36,1-33 (1959)).This proves that this hormone is the synthesizing of maturation, vitellin(Vt) of proteohormone and the growth that can influence sexual cell, the organ relevant with sexual gland.This hormone also influenced behavior after the octopus parents are laid eggs (Atlas of Endocrine organs, Japan Society for ComparativeEndocrinology.Ed., Kodansha).
1971, Schally etc. at first were separated to gonadotropin-releasing hormone (GnRH) from the pig hypothalamus, found that subsequently it is luteinizing hormone-releasing hormone (LRH) (LHRH).And determined its structure.After this, a large amount of researchists study GnRH.Up to now, in different vertebratess such as Mammals, bird and salmon, found that multiple GnRH. is same, manyly studies show that multiple invertebrates includes GnRH is had immunoreactive tissue and material (A.Di Cosmo and C.Di Cristo, J.Comp.Neuro., 398,1-12 (1998)).
Verified, in Mammals, GnRH is by the hypothalamus excretory and acts on pituitary gland, thereby causes that gonad-stimulating hormone discharges.These GnRH are decapeptides.
Yet, in octopus, be that the structure of gonad-stimulating hormone awaits to determine by their optic gland excretory though known gonadotropin as mentioned above.In addition, also from octopus, be not separated to GnRH, do not determine its structure yet.
Accordingly, one object of the present invention be exactly to identify and definite octopus in the structure of novel GnRH. another object of the present invention is to understand the activity of the GnRH in octopus and other invertebratess and the vertebrates, and its structure is determined by the present invention.
Further aim of the present invention provides novel peptide with as the useful reagent in relation between research GnRH structure and activity and the research higher animal neural system information processing mechanism.Further object of the present invention provides novel peptide with the basic compound as exploitation agricultural chemicals and medicine.
Another object of the present invention is to determine the precursor polypeptide of GnRH and the gene of this precursor polypeptide of encoding, so that the knowledge of expansion zoogeny aspect.Another object of the present invention provides the method for producing GnRH.
Of the present invention open
Once from octopus, separating in the trial of GnRH, by studying peptide in the activity aspect the heartbeat of enhancing animal, inventors of the present invention have carried out broad research to multiple physiologically active peptide, and these physiologically active peptides are brain samples of taking from about l00 kind 0.Vulgaris.As a result, inventors of the present invention separate and purifying have the peptide of following amino acid sequences (1), determined its structure, and by synthetic fully its structure of having verified:
<Glu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2?(1)
Wherein＜Glu represents Pyrrolidonecarboxylic acid.This peptide is called compound (1) hereinafter.Unless otherwise indicated, all amino acid are by the trigram coded representation of IUPAC naming system definition.
As shown in Figure 5, compound (1) has very high homology with the GnRH that identifies in vertebrates.Different with known decapeptide, proved that compound (1) is a dodecapeptide.
Inventors of the present invention further utilize quail to test, and prove that compound (1) has the GnRH activity, also, cause the activity of lutropin (LH) from the pituitary gland release of quail.
Inventors of the present invention have also prepared primer from above-mentioned aminoacid sequence, and on the total RNA that from the brain of 0.Vulgaris, obtains, utilize ThermoScript II polymerase chain reaction (RT-PCR) to carry out gene sequencing.Inventors of the present invention have determined that by this way propeptide polypeptide of the present invention has the full length amino acid primary sequence shown in SEQ ID NO:2.
Inventors of the present invention have determined that further the gene of coding precursor polypeptide has the base sequence shown in the SEQ IDNO:3, thereby have finished the present invention.
In addition, two amino-acid residue Asn-Tyr are inserted in N-terminal zone by the decapeptide GnRH between first＜Glu and second His, inventors of the present invention utilize the decapeptide GnRH that identifies from vertebrates to synthesize a kind of new peptide and have checked its physiologically active, and this peptide is with isolating from the brain of 0.Vulgaris and to have a peptide of aminoacid sequence (1) similar.
In other GnRH, have been found that chicken II type GnRH (cGnRH-II) shown in Figure 5 is prevalent in chicken and other multiple animals.Therefore, the N-terminal zone with two amino-acid residue Asn-Tyr insert the cGnRH-II between first＜Glu of peptide section and second His residue has obtained the represented new peptide of following amino acid sequences (2):
<Glu-Asn-Tyr-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH
2?(2)
Wherein＜Glu represents Pyrrolidonecarboxylic acid.This peptide is called compound (2) hereinafter.The activity of detection compound (2) aspect enhancing 0.Vulgaris heartbeat, we observe compound (2) and show and the similar activity of isolated compound (1) from the brain of 0.Vulgaris, but cGnRH-II does not show this activity.
In addition, inventors of the present invention make be separated to from invertebrates and have 2 and 3 amino acids in the active decapeptide of GnRH disappearance N-terminal zone, thereby be translated into a kind of and the similar decapeptide of isolating GnRH from vertebrates.As a result, we observe this decapeptide and have kept initial GnRH activity.
In order to redescribe, inventors of the present invention have determined that the represented peptide of following amino acid sequences (3) has the GnRH activity, and this peptide is to obtain by amino acid 2 and 3 is removed in the N-terminal zone of isolated compound (1) from the brain of 0.Vulgaris:
＜Glu-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2(3). wherein＜Glu represents Pyrrolidonecarboxylic acid.This peptide is called compound (3) hereinafter.
Accordingly, the invention provides and have gonadotropin-releasing hormone (GnRH) is active and have the decapeptide of following amino acid sequences (I):
<Glu-Zaa-Zaa-His-Zaa-Ser-Zaa-Zaa-Zaa-Zaa-Pro-Gly-NH
2?(I)
Wherein＜Glu represents Pyrrolidonecarboxylic acid, and Zaa represents any one amino acid.
Can limit more specifically peptide above-described, that have the active aminoacid sequence of GnRH (I) by following amino acid sequences (II):
<Glu-Zaa-Zaa-His-Zaa-Ser-Zaa-Gly-Zaa-Zaa-Pro-Gly-NH
2?(II)
Wherein＜Glu represents Pyrrolidonecarboxylic acid, and Zaa represents any one amino acid.
Can limit more specifically peptide above-described, that have the active aminoacid sequence of GnRH (I) by following amino acid sequences (III):
<Glu-Zaa-Zaa-His-Yaa-Ser-Zaa-Gly-Zaa-Zaa-Pro-Gly-NH
2?(III)
Wherein＜and Glu represents Pyrrolidonecarboxylic acid, and Zaa represents any one amino acid, and Yaa represents die aromatischen Aminosaeuren.
Provided by the invention have in the active peptide of GnRH, and especially preferred is those by following amino acid sequences (1), (2), (3) represented peptide:
<Glu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2?(1)
<Glu-Asn-Tyr-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH
2?(2)
<Glu-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2?(3)。
Wherein＜Glu represents Pyrrolidonecarboxylic acid.
The present invention further provides method of producing pharmaceutical preparation or sterilant and the method for producing young octopus, had an active aminoacid sequence of GnRH (I) and be used as activeconstituents and contain in pharmaceutical preparation or the sterilant.
According to one aspect of the present invention, the invention provides the precursor polypeptide, thereby and these precursor polypeptide contain the represented aminoacid sequence of SEQ ID NO:2, contain by the represented aminoacid sequence of SEQ ID NO:2 being carried out part is removed or replacing the aminoacid sequence that obtains or contain at those by the represented aminoacid sequence of SEQ ID NO:2 being carried out part and remove or replacing the sequence that interpolation 1 on the aminoacid sequence that obtains or a plurality of amino acid obtain.
According to another aspect of the present invention, the invention provides the peptide in the code book invention and the gene of precursor polypeptide thereof, gene, the carrier that has mixed these genes with the represented base sequence of SEQ ID NO:3 especially is provided, utilizes the host that these carriers transformed and utilized these genes and prepare the peptide among the present invention or the method for precursor polypeptide by genetically engineered.
The accompanying drawing summary
Fig. 1 illustrates the reversed-phase HPLC result, showed the final elution mode of compound (1), and compound (1) is the peptide in the embodiment of the invention 1.
Fig. 2 illustrates among the embodiment 5, with a certain amount of heartbeat of 0.Vulgaris when adding in the chamber corresponding to the peptide compounds among the present invention of a kind of 0.Vulgaris sample (1).
Fig. 3 comprises two charts, and they have showed the result of embodiment 5, wherein they showed ought be respectively with (a) 10
-5M cGnRH-II and (b) 10
-5The variation of 0.Vulgaris heartbeat when the peptide compounds among M the present invention (2) adds in the chamber respectively.
Fig. 4 is a chart, and it shows in embodiment 6, the amount of the lutropin (LH) that discharges when the peptide compounds among the present invention (1) is applied to the quail pituitary gland.
Fig. 5 is a comparative graph, and it has showed that the peptide compounds among the present invention (1) reaches the structure of the multiple gonadotropin-releasing hormone of identifying in different vertebratess.
Fig. 6 has showed the precursor amino acid sequence of polypeptide among the present invention, and wherein the part corresponding to the peptide section among the present invention marks with underscore.
Implement best mode of the present invention
Novel peptide provided by the invention can be done in order to cause that lutropin (LH) discharges and quicken the heartbeat of 0ctopus vulgaris from the quail pituitary gland.Therefore, on its active basis,, can from the brain of 0.vulgaris, separate and these peptides of purifying according to the following step to the 0.vulgaris heart:
In one embodiment, the hot water extract who has prepared the 0.vulgaris brain.Be added with 3% acetate in the extracting solution.With the extracting solution cooling, carry out centrifugal subsequently to obtain crude extract.Extract is adsorbed onto (for example, WATERS Co., the Ltd production of a C18 column extractor
Vac C18 column extractor) on, utilize 60% methyl alcohol that contains 0.1% trifluoroacetic acid to carry out wash-out subsequently to collect peptide moiety.Peptide moiety is carried out ion exchange chromatography, reversed phase chromatography or other chromatographic technique separates and purifying purpose peptide.
As a decapeptide, utilize by common peptide synthesizer (as PE biosystem JapanCo., the peptide synthesizer 433A that the Ltd. makes) solid-phase synthesis that carries out or other ordinary skills in the synthetic organic chemistry and just can synthesize peptide among the present invention easily.In the time of necessary, utilize thick peptide prod that these technology obtain to carry out purifying by common purification technique such as RPLC and crystallization.
Utilize following method can determine the precursor amino acid sequence of polypeptide of peptide section and the base sequence of the precursor polypeptide in the invention of definite code book:
Synthetic primer on the aminoacid sequence basis of the peptide that utilization obtains with aforesaid method carries out ThermoScript II polymerase chain reaction (RT-PCR) to the total RNA for preparing from the brain of 0.vulgaris, determine that gene order is about 750bp.Subsequently, utilize 5 '-RACE and 3 '-RACE technology determines respectively 5 ' and 3 ' terminal gene order. according to the present invention, determined that propeptide polypeptide of the present invention contains the aminoacid sequence shown in the SEQ ID NO:2, and the gene of this precursor polypeptide of having determined to encode contains the base sequence shown in the SEQ ID NO:3.
Therefore, can utilize recombinant DNA technology to prepare propeptide polypeptide among the present invention and the peptide among the present invention. when wanting to utilize recombinant DNA technology to prepare the precursor polypeptide, the carrier that has mixed the gene shown in SEQ ID NO:3 can be imported among the host and transform.Subsequently, cultivate the host or make its growth, from host or host's nutrient solution, separate and purifying purpose precursor polypeptide.
In order from the precursor polypeptide, to obtain the purpose peptide, can utilize enzyme that the precursor polypeptide is processed and modified.If necessary, can carry out isolated or purified to peptide prod.
Each peptide among the present invention all has the activity that strengthens the 0.vulgaris heartbeat and has the closely similar structure with vertebrate GnRH (peptide).These peptides also act on the pituitary gland of quail and cause that lutropin discharges.In addition, to studies show that the peptide among the present invention carries out, bird GnRH is relevant with the activity that strengthens the octopus heartbeat.These observations show jointly, the peptide among the present invention be actually with octopus and other invertebratess and vertebrates in the relevant hormone of release of gonadotropin.
Therefore, the peptide among the present invention can be used as octopus biology and the GnRH of research invertebrates and the useful materials of the structural relation between vertebrate GnRH that research comprises the reproduction mechanism of octopus.Therefore, these peptides have important effect in evolving zoologizeing. in addition, we wish that not only the peptide among the present invention has in the active novel substance of gonadotropin-releasing hormone in exploitation and has use, and wish that they play a role at the new technology aspect that utilizes aspect peptide itself or its analogue developing new drug and the sterilant and produce young octopus.
For example, the peptide among the present invention can be used as active ingredient of drugs, and acceptable vehicle is mixed with suitable oral and parenteral formulations, for example capsule, tablet and injection on pharmacology.Especially, the peptide among the present invention can mix with vehicle such as lactose, starch or their derivative or with derivatived cellulose, and wraps into and form capsule preparations in the gelatine capsule.
When we wanted that the peptide among the present invention is prepared into tablet, the vehicle that will be mentioned before added tackiness agent such as Xylo-Mucine, Lalgine and Sudan Gum-arabic and water outward.Subsequently this mixture is carried out kneading, and if necessary, just be made into particle.Subsequently, in mixture, add lubricant such as talcum powder and Magnesium Stearate and utilize common compressed tablets draft machine that it is prepared into tablet.
When we want that the peptide among the present invention is prepared into the preparation that is used for administered parenterally, be dissolved in sterile distilled water or Sterile Saline with solubilizing agent peptide and the ampoule that places sealing to be provided for the preparation of drug administration by injection.In the time of necessary, stablizer, buffer reagent or other additives can be added in the preparation.In addition, the peptide among the present invention can leave in the phial by powder type, like this, thereby just powder dissolution can be formed pharmaceutical solutions in sterile distilled water when using.These parenteral administrations can be sent by intravenously administrable or by intravenous drip.
Preferably,, comprise disease to be treated, patient's symptom, severity, patient's age and the route of administration of symptom, adjust containing as the dosage of the preparation of the peptide of the present invention of activeconstituents in view of multiple factor.When carrying out oral administration, the dosage of said preparation is generally 0.1-l000mg/ days/people, preferred 1-500mg/ days/people, and when carrying out administered parenterally, the dosage of said preparation can be about the 1/100-1/2 of oral administration.
In view of its GnRH essence, the peptide among the present invention can give the Cephalopoda animal, thereby makes animal just reach sexual maturity in early days, but so just induced animal begins to lay eggs in early days.Breed and raise these animal capable faster production young Cephalopoda animals.
Embodiment
Hereinafter will be described in detail the present invention, but this does not limit the intention of invention scope of the present invention by any way by embodiment.
Embodiment 1: centrifugation is in the peptide section of heart from 0.vulgaris
(a) the thick extraction
From 100 0.vulgaris samples, take out cerebral tissue (comprising optic gland, tractus opticus and optic lobe), freezing in liquid nitrogen.In 900ml distilled water, refrigerated tissue (180g) was boiled 10 minutes.After the cooling, add 3% acetate, with tissue homogenate and under 4 ℃, 12,000 * g centrifugal 30 minutes to obtain supernatant liquor.In pellet, add the acetate of 200ml3%, to mixture once more homogenate for use in extracting.Subsequently, under the same conditions mixture is carried out centrifugal to obtain supernatant liquor.Collect supernatant liquor and vacuum concentration to about 200ml so that crude extract to be provided.
(b) be adsorbed onto on the C18 extraction cartridge
In the crude extract that in step (a), obtains, add 5ml6MHCl, with this mixture at 4 ℃, 12, under the 000g centrifugal 30 minutes.The supernatant liquor that obtains is passed through Sep-
VacC18 extraction cartridge (10g, 35cc, WATERS Co., Ltd. produce) so that solute wherein be adsorbed onto on the extraction cartridge. subsequently, (TFA hereinafter) washes, and utilizes 100ml 60% methyl alcohol/0.1%TFA wash-out to be retained in the material on the post to utilize 200ml 0.1% trifluoroacetic acid.Eluate is carried out vacuum concentration and lyophilize, obtain 150mg dry labor thing.
(c) reversed phase high efficiency liquid phase column chromatography (1)
Utilize Capcell pak C18 UG80 (5 μ m, 10mm x 250mm, SHISEIDOCo., Ltd. manufacturing) that the dry labor thing that obtains in the above-mentioned steps (b) is carried out reversed phase high efficiency liquid phase column chromatography (rp-hplc).Especially, the dry labor thing that is dissolved among the 0.1%TFA (pH2.2) is crossed post with the speed of 1.5ml/min, utilizes acetonitrile linear gradient elution material retained, and be dissolved in acetonitrile concentration among the TFA in 60 minutes from 0% linear change to 60%.On the basis of 215nm uv-absorbing, elutriant is carried out the fraction collection of 3ml.
According to the scheme of describing among the embodiment 5 each part is carried out biological assay, found that, the part that elutes when acetonitrile concentration changes between 26%-30% has the activity that strengthens the 0.vulgaris heartbeat.
(d) cation exchange column chromatography
Utilize tsk gel SP-5PW (10 μ m, 7.5mm x 75mm, TOSOH Co., Ltd. manufacturing) that the active part that obtains in the above-mentioned steps (c) is carried out cation exchange column chromatography (cationic exchange HPLC).Particularly, join this active part in the post and utilize the flow velocity wash-out of 10mM phosphoric acid buffer (pH7.0) with 1.0ml/min, wherein the NaCl concentration in the phosphoric acid buffer was carried out linear change (linear gradient) from 0.1M to 0.6M in 60 minutes.Elutriant is carried out the fraction collection of 2ml and each collection part is carried out biological assay.The wash-out of collecting during for 0M when the NaCl concentration in the damping fluid partly has activity.
(e) reversed-phase HPLC (2)
Utilize Capcell pak C18 UG80 (5 μ m, 4.6mm x 150mm, SHISEIDOCo., Ltd. manufacturing) that the active part that obtains in the above-mentioned steps (d) is carried out reversed-phase HPLC.Particularly, join this active part in the post and utilize 0.1%TFA (pH2.2) to carry out wash-out with the flow velocity of 1.0ml/min, wherein the acetonitrile concentration among the TFA carried out linear change (linear gradient) from l0% to 30% in 60 minutes.Elutriant is carried out the fraction collection of 1ml.The part that wash-out goes out when the concentration of acetonitrile is about 19.5% has activity.
(f) reversed-phase HPLC (3)
Utilize Capcell pak C18 UG80 (5 μ m, 4.6mm x 150mm, SHISEIDOCo., Ltd. manufacturing) that the active part that obtains in the above-mentioned steps (e) is carried out reversed-phase HPLC.Particularly, this part is joined in the post, utilize the 0.1%TFA (pH2.2) contain 18% acetonitrile to carry out wash-out with the flow velocity of 0.5ml/min.When retention time is 17.5 minutes, obtain one and shown unimodal compound.With this compound called after compound (1).Fig. 1 has showed the result of reversed-phase HPLC.
Embodiment 2: the structure of compound (1) is determined
Because the N-terminal of modified exists, the aminoacid sequence of peptide is can not determine in the structural analysis that the compound (1) that utilizes Shimadzu PSQ-1 protein sequencing instrument (SHIMADZU Vo., Ltd. makes) that purifying among the embodiment 1 is obtained carries out.Therefore, the composition of the amino acid in the peptide is analyzed.
Table 1: the amino acid of peptide is formed
| Amino acid | pmol | Mol ratio |
| Asx | 51.1 | 1.5 |
| Glx | 42.6 | 1.3 |
| Ser | 32.7 | 1.0 |
| Gly | 70.0 | 2.1 |
| His | 57.9 | 1.7 |
| Pro | 37.1 | 1.1 |
| Tyr | 24.2 | 0.7 |
| Phe | 33.8 | 1.0 |
(Micromass, UK Co. Ltd.) determine the molecular weight of compound (1) by Q-TOF.The data that record are as shown in table 2 below.
Table 2: the mass-spectrometric data of peptide
| Compound | Molecular formula | Calculated value (M+2H) 2+ | Calculated value (M+2H) 2+ |
| Before enzyme is handled | C 66H 80N 20O 17 | 713.30 | 713.30 |
| After enzyme is handled | C 61H 75N 19O 15 | 657.79 | 657.85 |
Can determine that from amino acid composition analysis and molecular weight determination the N-terminal of compound (1) contains a Pyrrolidonecarboxylic acid.Accordingly, utilization can be excised enzyme (Ltd. produces for Pyrrolidonecarboxylic acid aminopeptidase, TAKARA SHUZO Co.) the processing compound (1) of first Pyrrolidonecarboxylic acid residue and be utilized the protein sequencing instrument to analyze once more.
As a result, determined the aminoacid sequence of compound (1) since second amino-acid residue, and the alleged occurrence Trp that can not detect by amino acid composition analysis.
The aminoacid sequence of determining is as shown in the table.
Table 3: the aminoacid sequence of the peptide after enzyme (pmol) is handled
| Circulation | Amino acid |
| 1 | Asn?27 |
| 2 | Tyr?25 |
| 3 | His?7 |
| 4 | Phe?23 |
| 5 | Ser?3 |
| 6 | Asn?16 |
| 7 | Gly?12 |
| 8 | Trp?3 |
| 9 | His?2 |
| 10 | Pro?5 |
| 11 | Gly?4 |
In order to guarantee that enzyme is handled is to act on according to desired, in the same way, utilize Q-TOF (Micromass, UK Co., Ltd.) molecular weight to the compound (1) after the enzyme processing redeterminates, and the result confirms to have excised first Pyrrolidonecarboxylic acid residue.The result is also as shown in table 2.
By aforesaid instrumental analysis, we have determined compound (1), promptly separate from 0.vulgaris and the neuropeptide of purifying, have following aminoacid sequence (1):
<Glu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2?(1)
Wherein＜Glu represents Pyrrolidonecarboxylic acid.
Embodiment 3: by solid phase synthesis process synthetic compound (1)
According to
Chemistry utilizes fully automated peptide synthesizer 433A (PEBiosystems Japan) synthetic compound (1).
In synthetic, utilize Fmoc-NH-SAL-A resin (WATANABE CHEMICALINDUSTRIES, Ltd. make) as solid support, and use Pyrrolidonecarboxylic acid, Fmoc-Asn-(Trt), Fmoc-Tyr-(tBu), Fmoc-His-(Trt), Fmoc-Phe, Fmoc-Ser-(tBu), Fmoc-Gly, Fmoc-Trp-(tBoc) and Fmoc-Pro simultaneously.
As used herein, Fmoc represents 9-fluorenyl methoxy carbonyl, and tBu represents the tertiary butyl, and Trt represents trityl, and tBoc represents the t-tert-butoxycarbonyl.
Building-up reactions finish and to thick peptide go the protection after, utilize 10ml contain the 100mg 2 methyl indole 2.5% 1, the mixture of 2-ethane two mercaptan/2.5% water/95%TFA cuts away thick peptide from peptide resin.After reaction is finished, reaction mixture is filtered. in filtered liquid, add ether so that the peptide precipitation.Utilize ether to precipitation flushing 3 times, obtain the thick peptide of about 100mg, subsequently the thick peptide of about 10mg is carried out purifying by reversed-phase HPLC, obtain the peptide of about 6mg purifying.
When utilizing Capcell pak C18 UG80 to carry out reversed-phase HPLC, the peptide of purifying is coming out with the identical retention time wash-out of compound (1).In addition, the synthetic peptide is showing the activity identical with native peptides aspect the heartbeat that strengthens 0.vulgaris.
Embodiment 4: by solid phase synthesis process synthetic compound (2) and (3)
Utilize with embodiment 3 above in identical method, synthesized following amino acid sequences (2) and (3) represented peptide:
<Glu-Asn-Tyr-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH
2?(2)
<Glu-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2?(3)。
Wherein＜Glu represents Pyrrolidonecarboxylic acid.
Embodiment 5: the heartbeat activity of measuring 0.vulgaris
Method according to propositions such as Morishita is measured (Fumihiro Morishita, Biochem.Biophys.Res.Commun., 240,354-358 (1997)) to 0.vulgaris heartbeat activity.Particularly, take out the heart of 0.vulgaris, and from heart, take out the atrium.From each atrium, insert intubate in ventricle, and utilize cotton thread to tie up simultaneously intubate is connected in the chamber (volume is 80ml). aorta is clamped in order to avoid liquid is revealed from ventricle, be connected with a pressure transmitter then.Heart after being ready to complete is used as working sample. adjust every conduit to the speed that allows synthetic sea water (containing 0.1% glucose) with 1-2ml/min and flow.Each analysans is dissolved in the identical synthetic sea water of 1ml, and this solution is expelled in the heart by intubate.The variation of record heartbeat.
Choose isolated compound from the brain of 0.vulgaris (1), compound (2) and cGnRH-II, vertebrates GnRH that from chicken, be separated to and that be used for derivative compound (2) as testing compound.
As shown in Figure 2, the result shows that compound (1) has strengthened the heartbeat of 0.vulgaris.
Shown in Fig. 3 (b), compound (2) has also strengthened the heartbeat of 0.vulgaris by raising heart rate and heartbeat amplitude.On the contrary, from as Fig. 3 (a) as can be seen, cGnRH-II does not influence heart rate and the heartbeat amplitude of 0.vulgaris.
Embodiment 6: to quail influence pituitary
Inoculation 7.54 x 10 in each hole of 24 orifice plates
5The individual quail cell pituitary (pituitary gland with two quails is suitable basically) of taking from.Subsequently, hatch these cells in containing the substratum of foetal calf serum, the time is 3 days.In 1ml does not contain the substratum of serum, these cells are not carried out extra 24 hours hatching.After hatching, respectively with 0,10
-9, 10
-8, 10
-7, 10
-6With 10
-5The final concentration of M adds peptide solution in substratum, and further these cultures is hatched 4 hours.From these cultures, collect supernatant liquor subsequently.On each concentration level, 5 samples are carried out radioimmunoassay and recording detection data.Utilize one-way analysis of variance (ANOVA) that data are carried out statistical study.
The result as shown in Figure 4.As shown in Figure 4, statistic analysis result shows, compound (1), and peptide promptly of the present invention has significantly improved the release of lutropin (LH).
Utilize identical method to detect, prove that compound (3) also can improve the release of lutropin (LH).
Embodiment 7: determine the complete amino acid structure of precursor polypeptide and determine the gene of coding this polypeptide
Base sequence
(1) total RNA of preparation 0.Vulgaris brain
In liquid nitrogen, the brain of about 1g0.vulgaris is pulverized, be dissolved in 10ml
Reagent (GIBCO BRL Co., Ltd) in and homogenate.Under the room temperature, homogenate was left standstill 5 minutes and was packed as the equal portions of 1ml.In each equal portions, add 200 μ l chloroforms, and stir this mixture. subsequently, (SAKUMA SEISAKUSHO Co. Ltd.) carries out centrifugal (15,000rpm, 15min, 4 ℃) to this mixture to utilize refrigerated centrifuge.After centrifugal, the sucking-off upper aqueous layer is also added the 0.5ml Virahol to aqueous phase.Subsequently, at room temperature this mixture being left standstill 10 minutes, utilize refrigerated centrifuge to carry out further centrifugal (15,000rpm, 10min, 4 ℃) then. the sucking-off supernatant liquor also will precipitate in the ethanol that is suspended in 1ml75% again.Suspension is carried out again centrifugal (10,000rpm, 5min, 4 ℃).Subsequently, remove supernatant liquor, will be deposited in air drying about 10 minutes.By under 60 ℃, hatching 10min the RNA flaky precipitate is dissolved in the 10 μ l DPEC treated waters.Utilize this method to obtain total RNA of about 3mg.
(2) 3 of degeneracy '-RACE
On the aminoacid sequence basis of isolating peptide from the brain of 0.vulgaris, design following degenerated primer and utilized usual way that they are synthesized:
Primer-1:5 '-CA (A/G) AA (C/T) TA (C/T) CA (C/T) TT (C/T) IIIAA (C/T) GG-3 '
(C/G) IAA (C/T) GGITGGCA (C/T) CCIGG-3 ' of primer-2:(T/A)
Wherein the foundation of each letter all is the definition (proving by experiment that to SHUJUNSHA Co., the cell engineering of Ltd. was replenished, and has hereinafter selected same code for use) of " nucleic acid code table ".
According to following rules, utilize 5 '/3 '-RACE test kit (Boehringer MannheimCo., Ltd.) carry out degeneracy 3 '-RACE: the synthetic damping fluid of the total RNA of 2 μ g, 4 μ l cDNA, 2 μ l dNTP mixtures, 1 μ l oligomerization dT anchor primer (12.5pmol/ μ l), 1 μ l AMV ThermoScript II (20 units/μ l) and DEPC treated water are added to together, make cumulative volume reach 20 μ l.Under 55 ℃, hatched this mixture 60 minutes, and under 65 ℃, hatched 10 minutes cDNA subsequently with synthetic article one chain.
Subsequently, according to following program carry out for the first time 3 '-RACE: with cDNA, 5 μ l, 10 x PCR damping fluids, 8 μ l dNTP mixtures, 5 μ l primers-1 (100pmol/ μ l), 1 μ l PCR anchor primer (12.5pmol/ μ l), the 0.5 μ l TaKaRaEx of 3 μ l article one chains
(TAKARA SHUZO Co., Ltd.) and water mix mutually, make cumulative volume reach 50 μ l.Hatched this mixture 5 minutes under 94 ℃, and carried out 30 circulations subsequently, each circulation was included in 94 ℃ following 30 seconds, 49 ℃ following 30 seconds and 72 ℃ following 2 minutes, carried out 5 minutes hatch at 72 ℃ after 30 circulations.(Perkin ElmerCo. Ltd.) carries out the PCR reaction to select GeneAmp PCR System 2400 thermal cyclers for use.
Subsequently, utilize spin post (MicroSpin S-400, Amersham PharmaciaCo., Ltd makes) to the first time PCR product carry out purifying, and according to follow procedure carry out for the second time 3 '-RACE: with 5 μ l product, 5 μ l10 x PCR damping fluids, 8 μ l dNTP mixtures, 5 μ l primers-2 (100pmol/ μ l), 1 μ l PCR anchor primer (12.5pmol/ μ l), the 0.5 μ l TaKaRa Ex of PCR for the first time
(TAKARA SHUZOCo., Ltd.) and water mix mutually, make its cumulative volume reach 50 μ l.Mixture was hatched under 94 ℃ 5 minutes, carry out 30 circulations subsequently, each circulation is included in 94 ℃ following 30 seconds, 51 ℃ following 30 seconds and 72 ℃ of following 1min, carries out hatching of 7min at 72 ℃ after 30 circulations.
Subsequently 5 μ l reaction mixtures are carried out electrophoresis on 1.5% sepharose.Observe and be about 400bp and about 600bp two bands, this shows that amplification has obtained two PCR products.
(3) collect the PCR product
5 μ l reaction mixtures are carried out electrophoresis and cut away two PCR product bands that form at about 400bp and about 600bp on 1.5% sepharose.(QIAGEN Co. Ltd) collects DNA from gel to utilize gel extraction kit.For the validating experiment result, respectively get the dna fragmentation that 3ml collects, on 1.5% sepharose, carry out electrophoresis.The result observes two PCR product bands that length is about 400bp and 600bp respectively.
(4) connect the PCR product
Utilize the spin post respectively the two PCR products that are about 400bp and 600bp to be carried out purifying.For each PCR product, PCR product, 2 μ l TA cloning vector pCR2.1 (Invitrogene Co. with 3 μ l, Ltd) and 5 μ l Ligation High (TOYOBO Co. Ltd) mutually mixes, and mixture is 16 ℃ of reactions 1 hour (ligation) down.
(5) colibacillary conversion
Respectively get two parts of bacillus coli DH 5 alpha (TOYOBO Co., Ltd) mixing that connect mixture and high energy that obtain in the 10 μ l steps (4).With mixture ice bath 30min, subsequently 42 ℃ of following heat shocks 50 seconds, then at cooled on ice 2min.After the cooling, to wherein adding the 1mlSOC substratum and under 37 ℃, hatching 10 minutes.Subsequently, 35 μ l X-gal are spread the LB/Amp nutrient agar surface of (LB contains the penbritin of 50ug/ml) uniformly, and 50 μ l transformant are inoculated so far on the substratum.Remaining transformant is 10, and centrifugal 1min makes its volume reach about 100 μ l under the 000rpm, then all transformant also is seeded in the LB/Amp nutrient agar.With this substratum 37 ℃ of following overnight incubation.
(6) bacterium colony PCR
The bacterium colony that utilizes previous step to obtain carries out bacterium colony PCR as template.Particularly, with Bacillus coli cells, 5 μ l 10x reaction buffers, 5 μ l 2mM dNTP, 3 μ l 25mM MgCl
2, 0.5 μ l M13FW primer (100pmol/ μ l), 0.5 μ l M13RV primer (100pmo l/ μ l), 0.5 μ l rTaq DNA polymerase (TOYOBO Co., Ltd) and water mix mutually, make its cumulative volume reach 50 μ l.Hatched this mixture 10 minutes under 90 ℃, and carried out 30 circulations subsequently, it is following 1 minute that each circulation is included in 94 ℃ following 30 seconds, 55 ℃ following 30 seconds and 72 ℃.3 μ l reaction mixtures are carried out electrophoresis on 1.5% sepharose.
Utilize synthetic M13FW of common method and M13RV primer, its base sequence is as follows:
M13FW：5′-GTAAAACGACGGCCAGTG-3′
M13RV：5′-GGAAACAGCTATGACCATG-3′
(7) dna sequence dna
Utilize the spin post bacterium colony PCR product of required size (about 600bp and about 800bp) to be carried out purifying and utilizes the dna sequence analysis test kit (PE biosystem Co. Ltd.) carries out sequential analysis to them.(PE biosystemCo. Ltd.) carries out sequential analysis to utilize ABI PRISM 310 genetic analysis instrument.
Utilize genetic analysis software GENETYX-MAC (SOFTWARE KAIHASTU Co.Ltd) that gene order is analyzed, determined to be about the cDNA sequence of 800bp.Further dna sequence analysis shows that the cDNA fragment that is about 600bp is actually the segmental part of the cDNA that is about 800bp.
(8)5′-RACE
Synthesized following primer according to the segmental base sequence of cDNA:
5′-RACE-1：5′-GGTCTGCAATCTCATTGACC-3′
5′-RACE-2：5′-TGCCAGTCAGGATTTCTCTC-3′
5′-RACE-3：5′-TCTTGGTGTTTGTCGGAAGG-3′
Utilize 5 '/3 '-RACE test kit (Boehringer Mannheim Co., Ltd.), with reference to following rules carry out 5 '-RACE: the total RNA of 2ug, 1 μ l 5 '-RACE-1 (12.5pmol/ μ l), the synthetic damping fluid of 4 μ l cDNA, 2 μ l dNTP mixtures, 1 μ l AMV ThermoScript II (20 units/μ l) and DEPC treated water are added to together, make cumulative volume reach 20 μ l.Under 55 ℃, hatched this mixture 60 minutes, and under 65 ℃, hatched other 10 minutes cDNA subsequently with synthetic article one chain.
After utilizing the spin column purification, the cDNA of article one chain is mixed with 2.5 μ l reaction buffers and 2.5 μ l 2mM dNTP, under 94 ℃, hatched this mixture 3 minutes, subsequently in cooled on ice.Subsequently, (10 units/μ l) add in this mixture with 1 μ l terminal enzyme (DNA), hatch this mixture 20 minutes under 37 ℃, hatch this mixture 10 minutes subsequently with the synthetic cDNA. that contains the dA tail under 70 ℃
Then, under following condition, carry out the first time and second time PCR:
(a) PCR for the first time
The cDNA, 5 μ l, 10 x PCR damping fluids, 8 μ l dNTP mixtures, 1 μ l 5 '-RACE-2 (12.5pmol/ μ l), 1 μ l oligomerization dT anchor primer (12.5pmol/ μ l), the 0.5 μ l TaKaRa Ex that 3 μ l are contained the dA tail
(TAKARA SHUZO Co., Ltd.) and water mix mutually, make cumulative volume reach 50 μ l. and under 94 ℃, hatched this mixture 5 minutes, carry out 30 circulations subsequently, each circulation is included in 94 ℃ following 30 seconds, 55 ℃ following 30 seconds and 72 ℃ of following 3min, carries out hatching of 5min after 30 circulations under 72 ℃.
(b) PCR for the second time
With first time PCR product, 5 μ ls 10 x PCR damping fluids, 8 μ l dNTP mixtures, 1 μ l 5 '-RACE-3 (12.5pmol/ μ l), l μ l PCR anchor primer (12.5pmo l/ μ l), the 0.5 μ l TaKaRa Ex of 5 μ l behind the spin column purification
(TAKARASHUZO Co., Ltd.) and water mix mutually, make volume reach 50 μ l.Utilization is subsequently carried out PCR with the cycling condition that PCR is identical for the first time.
Utilize 1.5% sepharose to the second time PCR product carry out electrophoretic analysis.The result observes the band that is about 600bp.
According to above (4), (5), (6) and (7) middle rules of describing are determined the base sequence of PCR product for the second time.
By the analysis of front, determined size (about 700bp) and the base sequence of cDNA of the gene of the propeptide polypeptide in the code book invention.In addition, the amino acid estimated number (89 amino-acid residues) and the aminoacid sequence of the propeptide polypeptide among the present invention have been determined.
The base sequence of the gene (cDNA) of precursor amino acid sequence of polypeptide and coding precursor polypeptide is respectively shown in SEQ ID NO:2 and SEQ ID NO:3.In addition, Fig. 6 has showed the partial amino-acid series corresponding to the propeptide polypeptide among the present invention
In Fig. 6, mark with underscore corresponding to the aminoacid sequence of the peptide among the present invention.
Embodiment 8: demonstrative preparation
Tablet
Form:
Compound (1) 10g
Lactose 125g
Micro-crystalline cellulose 25g
W-Gum 25g
5% Vltra tears 100ml
Magnesium Stearate 5g
In accordance with known methods, mentioned component is carried out kneading, granulation, drying and typing to obtain tablet, every heavy 190mg also contains 100mg compound (1) as activeconstituents.
Industrial applicability
As shown in Figure 5, the peptide that can act on the heartbeat that strengthens 0.Vulgaris among the present invention has the structure highly similar with vertebrate gonadotropin-releasing hormone (peptide). and find therewith to combine, the peptide among the present invention can act on the quail pituitary and cause lutropin to discharge this fact and mean that peptide is actually the hormone (peptide) relevant with the octopus gonadotropin releasing hormone among the present invention.
Therefore, activity research of the peptide among the present invention is helped to understand octopus biology and the zoogeny process of the reproduction mechanisms that comprises octopus.
Peptide among the present invention not only can be used as useful tool and is used for the novel substance that exploitation has the gonadotropin-releasing hormone activity, and can utilize the analog of peptide itself or peptide to come developing new drug and pesticide, and exploitation is for the production of the new technology of young octopus.
Sequence table
＜110〉Suntory Ltd
＜120〉encoding gene of Xin Ying gonadotropin-releasing hormone, its precursor peptide and precursor peptide thereof
<130>SN-50
<150>JP2000-198430
<151>2000-06-30
<160>3
<170>PatentIn?Ver.2.1
<210>1
<211>12
<212>PRT
<213>OCTOPUS?VULGARIS
<220>
＜221〉peptide
<222>(1)..(12)
＜223〉Xaa is the Pyrrolidonecarboxylic acid residue, also is＜Glu.Its C-end has carried out amidation.
<400>1
<210>2
<211>89
<212>PRT
<213>OCTOPUS?VULGARIS
<220>
＜221〉peptide
<222>(1)..(89)
<400>2
<210>3
<211>770
<212>DNA
<213>OCTOPUS?VULGARIS
<220>
<221>CDS
<222>(92)..(358)
<400>3
Claims (14)
1. it is active and have the peptide of following aminoacid sequence (I) to have gonadotropin-releasing hormone (GnRH):
<Glu-Asn-Tyr-His-Zaa-Ser-Zaa-Zaa-Zaa-Zaa-Pro-Gly-NH
2(I)
Wherein＜Glu represents Pyrrolidonecarboxylic acid; Zaa represents any one amino acid.
2. claim 1 has an active peptide of GnRH, and it has following aminoacid sequence (II):
＜Glu-Asn-Tyr-His-Zaa-Ser-Zaa-Gly-Zaa-Zaa-Pro-Gly-NH
2(II) wherein＜Glu represents Pyrrolidonecarboxylic acid, and Zaa represents any one amino acid.
Claim 1 or 2 have an active peptide of GnRH, it has following aminoacid sequence (III):
＜Glu-Asn-Tyr-His-Yaa-Ser-Zaa-Gly-Zaa-Zaa-Pro-Gly-NH
2(III) wherein＜and Glu represents Pyrrolidonecarboxylic acid, and Zaa represents any one amino acid, and Yaa represents die aromatischen Aminosaeuren.
4. each peptide among the claim 1-3 that from the brain of Octopus vulgaris, obtains.
5. each peptide among the claim 1-4, it has following aminoacid sequence (1):
＜Glu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH
2(1) wherein＜Glu represents Pyrrolidonecarboxylic acid.
6. each peptide among the claim 1-3, the aminoacid sequence that it has be by two amino-acid residue Asn-Tyr are inserted first amino acids (＜Glu) and the N-terminal of the vertebrates GnRH between second amino acids (His) zone obtain.
7. the peptide with following aminoacid sequence (2) of claim 6:
＜Glu-Asn-Tyr-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH
2(2) wherein＜Glu represents Pyrrolidonecarboxylic acid.
8. coding has the dna fragmentation of the polypeptide of the represented aminoacid sequence of SEQ ID NO:1 or SEQ ID NO:2.
9. the dna fragmentation that has the represented base sequence of SEQ ID NO:3.
10. the dna fragmentation that can hybridize with the dna fragmentation of claim 8 or 9.
11. can mix the carrier of each dna fragmentation among the claim 8-10.
12. utilize the carrier host transformed in the claim 11.
13. preparation has the method for the active propeptide polypeptide of gonadotropin-releasing hormone (GnRH), may further comprise the steps:
Host in the claim 12 is cultivated or makes its growth; And
Collect from the host or in host's nutrient solution and have the active propeptide polypeptide of GnRH.
14. preparation has the method for the active peptide of gonadotropin-releasing hormone (GnRH), may further comprise the steps:
From have the active propeptide polypeptide of GnRH, cut and have the active propeptide of GnRH, and this precursor polypeptide is to utilize the method in the claim 13 to obtain; And
Subsequently the C-terminal and the N-terminal of precursor are modified.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP198430/00 | 2000-06-30 | ||
| JP2000198430 | 2000-06-30 | ||
| JP198430/2000 | 2000-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1440422A CN1440422A (en) | 2003-09-03 |
| CN100497384C true CN100497384C (en) | 2009-06-10 |
Family
ID=18696596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018122795A Expired - Fee Related CN100497384C (en) | 2000-06-30 | 2001-06-29 | Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7381706B2 (en) |
| EP (1) | EP1298142A4 (en) |
| KR (1) | KR20030021184A (en) |
| CN (1) | CN100497384C (en) |
| AU (1) | AU2001267872A1 (en) |
| CA (1) | CA2414635A1 (en) |
| WO (1) | WO2002002628A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170048375A (en) | 2014-08-01 | 2017-05-08 | 코닝 인코포레이티드 | Screen printing apparatus and methods |
| CN113388019A (en) * | 2018-01-25 | 2021-09-14 | 浙江海洋大学 | Application of sepiella maindroni neuropeptide |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4530920A (en) * | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
| US5075224A (en) * | 1984-10-19 | 1991-12-24 | Genentech, Inc. | Prepro-LHRH C-terminal peptide DNA |
| US5643877A (en) * | 1994-12-05 | 1997-07-01 | University Of Maryland Biotechnology Institute | Compounds comprising gonadotropin releasing hormone (GnRH) and methods for controlling reproduction in fish |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
-
2001
- 2001-06-29 CN CNB018122795A patent/CN100497384C/en not_active Expired - Fee Related
- 2001-06-29 WO PCT/JP2001/005607 patent/WO2002002628A1/en active Application Filing
- 2001-06-29 EP EP01945691A patent/EP1298142A4/en not_active Withdrawn
- 2001-06-29 AU AU2001267872A patent/AU2001267872A1/en not_active Abandoned
- 2001-06-29 KR KR1020027017986A patent/KR20030021184A/en not_active Application Discontinuation
- 2001-06-29 US US10/312,637 patent/US7381706B2/en not_active Expired - Fee Related
- 2001-06-29 CA CA002414635A patent/CA2414635A1/en not_active Abandoned
-
2008
- 2008-04-29 US US12/111,725 patent/US20080280326A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1440422A (en) | 2003-09-03 |
| US20080280326A1 (en) | 2008-11-13 |
| AU2001267872A1 (en) | 2002-01-14 |
| KR20030021184A (en) | 2003-03-12 |
| CA2414635A1 (en) | 2002-01-10 |
| WO2002002628A1 (en) | 2002-01-10 |
| EP1298142A4 (en) | 2005-12-21 |
| EP1298142A1 (en) | 2003-04-02 |
| US20050143567A1 (en) | 2005-06-30 |
| US7381706B2 (en) | 2008-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Falciani et al. | Class 3 Hox genes in insects and the origin of zen. | |
| Nachman et al. | Leucosulfakinin, a sulfated insect neuropeptide with homology to gastrin and cholecystokinin | |
| AU681216B2 (en) | Conotoxin peptides | |
| Mullally et al. | Synthetic peptides corresponding to a-lactalbumin and b-lactoglobulin sequences with angiotensin-1-converting enzyme inhibitory activity | |
| WO2015156649A1 (en) | Peptide having fibrosis inhibitory activity and composition containing same | |
| RU2002128757A (en) | POLYEPEPTIDE, PROTEASE, DNA, VECTOR, METHOD FOR PRODUCING PROTEASE, COMPOUNDS, COMPOSITIONS, METHOD FOR INHIBITING ACTIVITY, METHOD OF TREATMENT | |
| WO2013169077A1 (en) | Composition for preventing or treating cachexia | |
| NO171788B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PHOSPHINIC ACID DERIVATIVES | |
| WO2001002424A2 (en) | Peptide boronic acid inhibitors of hepatitis c virus protease | |
| Fónagy et al. | Isolation, primary structure and synthesis of neomyosuppressin, a myoinhibiting neuropeptide from the grey fleshfly, Neobellieria bullata | |
| WO2012050402A2 (en) | Cell-permeable recombinant parkin protein and a pharmaceutical composition for treating degenerative brain diseases containing the same | |
| WO2016190660A1 (en) | Novel peptide and composition containing the same | |
| US5633347A (en) | Conotoxin peptides | |
| WO2018074682A1 (en) | Peptide having anti-obesity and anti-diabetes efficacy and use thereof | |
| US5843900A (en) | Bradykinin antagonists | |
| Bylemans et al. | Neb‐colloostatin, a second folliculostatin of the grey fleshfly, Neobellieria bullata | |
| CN100497384C (en) | Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same | |
| AU700066B2 (en) | Polypeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone | |
| KR19990087123A (en) | Peptide derivative | |
| Komiyama et al. | The primary structure of rat parathymosin. | |
| WO2016027990A1 (en) | Pharmaceutical composition containing dusp5 as active ingredient for preventing or treating bone metabolic diseases | |
| LU86683A1 (en) | PEPTIDE VENIN OF SNAKE STOPPING GROWTH | |
| WO2016098936A1 (en) | Osteogenic peptide and use of same | |
| US5589340A (en) | Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides | |
| Braren et al. | Use of the EST database resource to identify and clone novel mono (ADP-ribosyl) transferase gene family members |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SUNTORY HOLDINGS CO., LTD. Free format text: FORMER OWNER: SUNTORY LTD. Effective date: 20090710 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090710 Address after: Osaka City, Osaka of Japan Patentee after: Suntory Holdings Limited Address before: Osaka City, Osaka of Japan Patentee before: Suntory Ltd. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 Termination date: 20110629 |